Actively Recruiting
Phase 2 Study of Oral INCB123667 for Women with Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Led by Incyte Corporation · Updated on 2026-08-06
160
Participants Needed
74
Research Sites
25 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of INCB123667 in women with platinum-resistant ovarian cancer that shows cyclin E1 overexpression. This phase 2, single-arm study focuses on participants whose cancer has not responded well to previous platinum-based treatments, aiming to explore new therapeutic options for this condition. Participants will receive INCB123667 orally twice daily at doses determined by their tumors cyclin E1 expression levels. The study includes multiple cohorts receiving this treatment according to the protocol. The treatment period and dosing follow specific guidelines based on tumor characteristics to assess the drugs impact. Throughout the study, participants will be monitored for treatment response and safety for up to two years. Assessments include evaluating tumor response by independent review and investigator evaluation, measuring progression-free and overall survival, and tracking any adverse events related to the treatment. This close monitoring helps researchers understand the treatments effects and safety profile over time.
CONDITIONS
Brief Title
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
